Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 05/04 09:10:28 pm
112.19 USD   -0.44%
08:50aDJJ&J Appeals $127 Million in Awards in Talc Cancer Cases -- WSJ
05/03 PHARMACYTE BIOT : Appoints Former Johnson & Johnson Executive as Sen..
05/03 JOHNSON & JOHNS : ordered to pay $55m in talc-powder trial
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2012 | 11:11am CEST

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on JOHNSON & JOHNSON
08:50aDJJ&J Appeals $127 Million in Awards in Talc Cancer Cases -- WSJ
05/03 PHARMACYTE BIOTECH : Appoints Former Johnson & Johnson Executive as Senior Busin..
05/03 JOHNSON & JOHNSON : Crisis management is key of gov't media strategy
05/03 JOHNSON & JOHNSON : ordered to pay $55m in talc-powder trial
05/03 JOHNSON & JOHNSON : ordered to pay $55 million in talcum powder cancer case
05/03DJPfizer Guides Higher, Mulls Breakup of Company
05/03 JOHNSON & JOHNSON : ordered to pay $55 million in talc-powder trial
05/03 JOHNSON & JOHNSON : St. Louis jury awards $55M in Johnson & Johnson cancer suit
05/03 JOHNSON & JOHNSON : Another big verdict in talc case against Johnson & Johnson
05/03 JOHNSON & JOHNSON : US court orders Johnson & Johnson to pay $55 million in talc..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials